Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - TACC3 |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - TACC3 | intrahepatic cholangiocarcinoma | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment inhibited Fgfr2 signaling and reduced growth and viability of cells derived from a TP53-null intrahepatic cholangiocarcinoma mouse model expressing FGFR2-TACC3 fusion in tumoroid and 2D cell culture (PMID: 33741397). | 33741397 |
FGFR2 - TACC3 | intrahepatic cholangiocarcinoma | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) treatment inhibited growth and viability of cells derived from a TP53-null intrahepatic cholangiocarcinoma mouse model expressing FGFR2-TACC3 fusion in tumoroid and 2D cell culture (PMID: 33741397). | 33741397 | |
FGFR2 - TACC3 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical | Actionable | In a preclinical study, Truseltiq (infigratinib) prevented oncogenic transformation of cells expressing FGFR2-TACC3 (PMID: 26048680). | 26048680 |
FGFR2 - TACC3 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment induced apoptosis, and inhibited Fgfr and Erk phosphorylation, cell proliferation, and tumor growth in a mouse cell line allograft model expressing FGFR2-TACC3 (PMID: 30067876). | 30067876 |
FGFR2 - TACC3 | Advanced Solid Tumor | sensitive | Ganetespib | Preclinical | Actionable | In a preclinical study, Ganetespib treatment induced apoptosis, and inhibited Fgfr and Erk phosphorylation, cell proliferation, and tumor growth in a mouse cell line allograft model expressing FGFR2-TACC3 (PMID: 30067876). | 30067876 | |
FGFR2 - TACC3 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Ganetespib + Infigratinib | Preclinical | Actionable | In a preclinical study, Truseltiq (infigratinib) and Ganetespib combination treatment led to enhanced apoptosis, and inhibited Fgfr and Erk phosphorylation, cell proliferation, and tumor growth in a mouse cell line allograft model expressing FGFR2-TACC3, and demonstrated improved efficacy over either agent alone (PMID: 30067876). | 30067876 |
FGFR2 - TACC3 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Ponatinib | Preclinical | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing the fusion, FGFR2 - TACC3 (PMID: 26048680). | 26048680 |
FGFR2 - TACC3 | intrahepatic cholangiocarcinoma | sensitive | FGFR Inhibitor (Pan) | Infigratinib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) and Mekinist (trametinib) combination treatment synergistically reduced viability of cells derived from a TP53-null intrahepatic cholangiocarcinoma mouse model expressing FGFR2-TACC3 fusion (PMID: 33741397). | 33741397 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|